Search research articles
Contact Us
Filters
Showing results (31-40 of 161) with videos related to
Page
of 17
Sort By:
British Journal of Clinical Pharmacology
|
December 5, 2025
Community pharmacies in Italy: An inevitably growing role?
Livio Garattini, Bruno Finazzi
Applied Health Economics and Health Policy
|
March 19, 2016
'Appropriateness' in Italy: A 'Magic Word' in Pharmaceuticals?
Livio Garattini, Anna Padula
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
December 28, 2019
Defensive medicine in Europe: a 'full circle'?
Livio Garattini, Anna Padula
Journal of the Royal Society of Medicine
|
November 16, 2019
Health technology assessment for pharmaceutical regulation in the European Union: do we need another body?
Anna Padula, Livio Garattini
Journal of the Royal Society of Medicine
|
December 21, 2019
Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?
Livio Garattini, Anna Padula
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
January 11, 2020
Defensive medicine in Europe: a 'full circle'?
Livio Garattini, Anna Padula
Applied Health Economics and Health Policy
|
February 5, 2020
Comment on: 'Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition'
Livio Garattini, Nick Freemantle
Journal of the Royal Society of Medicine
|
December 4, 2018
Competition in health markets: is something rotten?
Livio Garattini, Anna Padula
Applied Health Economics and Health Policy
|
November 29, 2021
Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid?
Livio Garattini, Bruno Finazzi
Croatian Medical Journal
|
June 13, 2019
Precision medicine and monoclonal antibodies: breach of promise?
Livio Garattini, Anna Padula
Page
of 17
Search research articles
Search
Showing results (31-40 of 161) with videos related to
Sort By:
Page
of 17
British Journal of Clinical Pharmacology
|
December 5, 2025
Community pharmacies in Italy: An inevitably growing role?
Livio Garattini, Bruno Finazzi
Applied Health Economics and Health Policy
|
March 19, 2016
'Appropriateness' in Italy: A 'Magic Word' in Pharmaceuticals?
Livio Garattini, Anna Padula
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
December 28, 2019
Defensive medicine in Europe: a 'full circle'?
Livio Garattini, Anna Padula
Journal of the Royal Society of Medicine
|
November 16, 2019
Health technology assessment for pharmaceutical regulation in the European Union: do we need another body?
Anna Padula, Livio Garattini
Journal of the Royal Society of Medicine
|
December 21, 2019
Pharmaceutical expenditure control in Europe: time to move from pricing to budgeting?
Livio Garattini, Anna Padula
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
January 11, 2020
Defensive medicine in Europe: a 'full circle'?
Livio Garattini, Anna Padula
Applied Health Economics and Health Policy
|
February 5, 2020
Comment on: 'Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition'
Livio Garattini, Nick Freemantle
Journal of the Royal Society of Medicine
|
December 4, 2018
Competition in health markets: is something rotten?
Livio Garattini, Anna Padula
Applied Health Economics and Health Policy
|
November 29, 2021
Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid?
Livio Garattini, Bruno Finazzi
Croatian Medical Journal
|
June 13, 2019
Precision medicine and monoclonal antibodies: breach of promise?
Livio Garattini, Anna Padula
Page
of 17